| Literature DB >> 35496992 |
Umar Shahbaz1,2, Nazira Fatima3, Samra Basharat4, Asma Bibi5, Xiaobin Yu1,2, Muhammad Iftikhar Hussain1, Maryam Nasrullah6.
Abstract
Vitamin C stands as an essential water-soluble vitamin, antioxidant and has been shown to enhance immunity. SARS-CoV-2 has been spreading rapidly across the worldwide, several cellular processes of innate and adaptive immunity are aided by vitamin C, which strengthens the immune system overall. Multiple lines of evidence in the literature associate vitamin C with antioxidant, anti-inflammatory, anticoagulant and immunomodulatory actions. Pneumonia and sepsis patients had poor ascorbic acid status and high oxidative stress, according to many studies. Pneumonia patients who get vitamin C may have less severe symptoms and a longer course of the illness if they do. To standardize plasma levels in sepsis patients, gram measurements of the vitamin must be administered intravenously (IV). This intervention has been shown in a few trials to reduce mortality. COVID-19 management in China and the United States has exhibited remarkable results when using a high percentage of intravenous vitamins C. It's acceptable to include vitamin C in the COVID-19 treatment protocol as a secondary measure based on the current active clinical studies looking at the impact of vitamin C on the management of COVID-19. Patients with hypovitaminosis C or severe respiratory illnesses, such as COVID-19, may benefit from taking vitamin C, due to its good safety profile, simplicity of use, and potential for rapid production scaling. The study's goal was to see whether high dosage intravenous vitamin C had any impact on individuals with severe COVID-19 (HDIVC). Finally we discuss recent research that has been published on the efficacy of vitamin C administration in the treatment of viral infection and life-threatening conditions. The purpose of this manuscript is to summarise existing research on the efficacy of vitamin C as a treatment for COVID-19 and to discuss possible explanations for why it may work in some individuals but not in others.Entities:
Keywords: COVID-19; SARS-CoV-2; anti-oxidant; antiviral; sepsis; vitamin C
Year: 2022 PMID: 35496992 PMCID: PMC8995185 DOI: 10.3934/microbiol.2022010
Source DB: PubMed Journal: AIMS Microbiol ISSN: 2471-1888
Figure 1.An IA administration of vitamin C to enhance the specific functions of immune system [11].
Ongoing clinical trial for using Vitamin C for COVID-19 patient treatment.
| S.No. | Study no | country | Participant | intervention | Register with |
| 1 |
| USA | 630 COVID-19 Patients | Trial arms: Vit C + folic acid Hydroxychloroquine +Folic Acid |
|
| 2 |
| Wuhan, China | 140 COVID-19 Patients | 12 g Vitamin C, IV, every 12 hours |
|
| 3 |
| Mashhad | 20 COVID-19 patients | MCN (Methylene blue, vitamin C, N-acetyl cysteine) |
|
| 4 | ChiCTR2000033050 | Shanghai, China | 110 COVID-19 patients | High dose of Vit C IV to COVID-19 patient |
|
| 5 | TCTR20200404004 | Bangkok, Thailand | 400 COVID-19 patients | Chloroquine 10 mg base/kg once in a 24 hour, Vit C 1000 mg in 24 hours. |
|
| 6 | ChiCTR2000032717 | Xian, Shaanxi, China | 60 COVID-19 patients | High dose of vit C + Chinese medicine |
|
| 7 |
| Virginia, USA | 20 COVID-19 patients | Vit C (IV 50 mg/kg) 4 days, with an interval of 6 hours. |
|
| 8 | ACTRN12620000557932 | Australia, Germany, USA | 200 COVID-19 patients | 1.Hydroxychloroquine + Zn+ Vit D3/B12+ azithromycin + IV Vit C |
|
| 9 |
| Sherbrooke, Quebec, Canada | 800 COVID-19 patients | Vit C (IV 50 mg/kg) every 6 hours |
|
| 10 | ChiCTR2000029768 | Wuhan, China | 600 COVID-19 patients | Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150 mg, Tid), Oral Vit C tablets (5 g) every day |
|
| 11 |
| Palermo, Italy | 500 COVID-19 patients | Vit C (IV 10 g) + conventional therapy |
|
| 12 | IRCT20200324046850N5 | Abadan, Khuzestan Province, Iran | 40 COVID-19 patients | Hydroxychloroquine 200 mg + Vit C (oral 500 mg) for 5 days with an interval of 12 hours |
|
| 13 |
| Richmond, Virginia, USA | 200 COVID-19 patients | Vit C (IV 100 mg/kg) every 8 hours |
|
| 14 | ChiCTR2000032716 | Shanghai, China | 12 COVID-19 patients | High dose of Vit C IV treatment upon diagnosis of severe COVID-19 patients |
|
| 15 |
| USA | 520 COVID-19 patients | 1. 2–3 doses of Vit C 8000 mg |
|
| 16 |
| Victoria, Australia | 200 COVID-19 patients | IV vitamin C, Hydroxycholorquine, azithromycin, Zinc citrate, Vitamin D3, Vitamin B12 for treating COVID-19 |
|
| 17 |
| Quebec, Canada | 800 COVID-19 patients | Vit C (IV 50 mg/kg) every 6 hours for 96 hours |
|
| 18 | ChiCTR2000032400 | Shanghai, China | 120 COVID-19 patients | Vit C (IV 100 mg/kg) daily |
|
| 19 |
| USA | 66 COVID-19 patients | Increasing dose of Vit C oral (0.3 g/kg, 0.6 g/kg, 0.9 g/kg) every 6 hours |
|